Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibromatosis 2 × HDAC-42 × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1

Interventions

temsirolimus 1 neratinib 1 brigatinib 1 Valproic Acid 1 Sirolimus 1 Immunoglobulin G 1 HDAC-42 1 Doxycycline 1 Disulfides 1 Cetuximab 1 Bevacizumab 1 Aspirin 1 AZD 6244 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05130866 2025-10-07

POPLAR-NF2

Recursion Pharmaceuticals Inc.

Phase 2/3 Terminated

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡